Low-dose CT screening for patients at high risk of lung cancer can find smaller nodules than X-ray, but concern remains about potential harm from the test.
Low-dose CT screening for patients who are at increased risk of developing lung cancer can identify smaller nodules than can chest X-rays. But concern remains regarding potential harm from the screening, according to a study published online in JAMA.
Peter B. Bach, MD, of the Memorial Sloan-Kettering Cancer Center, New York, and colleagues assessed the results of several randomized controlled trials and cohort studies, finding that the National Lung Screening trial was the most informative, with 53,545 participants. The findings showed that the screening resulted in a 20 percent lower relative risk of death.
“In terms of potential harms of [low-dose CT] screening, across all trials and cohorts, approximately 20 percent of individuals in each round of screening had positive results requiring some degree of follow-up, while approximately 1 percent had lung cancer,” the study authors wrote.
“There was marked heterogeneity in this finding and in the frequency of follow-up investigations, biopsies, and percentage of surgical procedures performed in patients with benign lesions.”
The study authors concluded, however, that there is still uncertainty about the potential harms of screening and generalizability of the results.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.